MindBio Therapeutics (CNSX: MBIO) and Enveric Biosciences (NASDAQ: ENVB) are collaborating to advance treatments for neuropsychiatric disorders through microdosing psychedelics, such as their novel psilocin prodrug candidates. This partnership represents…
Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics for the out-licensing of a class of psilocin prodrugs (NPP) aimed at treating mental health disorders. The NPP molecules…
Enveric Biosciences, Inc. (NASDAQ: ENVB) told investors it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO),…
In a groundbreaking move within the pharmaceutical industry, Enveric Biosciences (NASDAQ: ENVB) a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety,…
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today…
Psychedelics biotech firm, Enveric Biosciences has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, British Columbia-based biopharma company MindBio Therapeutics Corp CSE:…
Enveric Biosciences, a notable player in biotechnological innovations, has recently announced a significant licensing agreement that might change the landscape of cancer treatment. According to a recent press release from…
Enveric Biosciences, a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at…
Mental health disorders have long been a significant global challenge, affecting millions of individuals and placing an immense burden on healthcare systems worldwide. Despite substantial investments in research and development,…
In a significant stride toward transforming the landscape of joint disease treatment, Enveric Biosciences has inked two non-binding term sheets with a yet undisclosed biotechnology company. This promising collaboration is…